Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:01 AM
Ignite Modification Date:
2025-12-25 @ 2:01 AM
NCT ID:
NCT00842660
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed primary squamous cell carcinoma of the uterine cervix.
* Previously untreated disease.
* Clinical FIGO stage III-IVa or pelvic/para-aortic lymph node positive by PET examination.
* No known metastases to supraclavicular nodes or other organs outside the radiotherapy field.
* Ages eligible: 35 years - 70 years.
* Patients must have adequate bone marrow, pulmonary, liver and renal function documented before radiotherapy. WBC \> 3000/mm3, platelet \> 100,000/mm3, serum transaminases (GOT, GPT) \< 60 IU/ml, total bilirubin \< 1.5mg%, creatinine \< 1.4mg% (creatinine clearance \> 60 ml/min).
* Performance status 0 or 1 (see Appendix I).
* The interval between RT and randomization is not greater than 3 weeks.
* Patients must have signed informed consent to participate this study.
Exclusion Criteria:
* Age \> 70 or \< 35
* Medical or psychological condition that would preclude treatment.
* Previous chemotherapy or pelvic RT.
* Small cell carcinoma, adenocarcinoma or adenosquamous carcinoma.
* Patient unreliable for treatment completion and follow-up.
Healthy Volunteers:
True
Sex:
FEMALE
Minimum Age:
35 Years
Maximum Age:
70 Years
Study:
NCT00842660
Study Brief:
Protocol Section:
NCT00842660